Literature DB >> 20685273

Core histone H2A ubiquitylation and transcriptional regulation.

Miki Higashi1, Satoshi Inoue, Takashi Ito.   

Abstract

Diverse histone modifications, such as acetylation, methylation and ubiquitylation have been linked to the regulation of cellular activities such as transcription, repair and replication. The mechanisms by which histone modifications contribute to the transcription process are not fully understood; however increasing evidence suggests that they work together in the form of a histone code to regulate the recruitment of chromatin-modulating factors [1-3]. Histone ubiquitylation has been found to be an important chromatin modification with roles in trans-histone modification and transcriptional regulation. In the past several years, there has been dramatic progress in the identification of factors that control ubiquitin attachment to the histone. Recent advances concerning core histone H2A ubiquitylation and transcriptional regulation will be reviewed and the cellular functions of these histone modifications will be discussed.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685273     DOI: 10.1016/j.yexcr.2010.05.028

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

Review 1.  Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.

Authors:  Gerald V Denis
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

2.  Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks.

Authors:  Lilach Moyal; Yaniv Lerenthal; Mali Gana-Weisz; Gilad Mass; Sairei So; Shih-Ya Wang; Berina Eppink; Young Min Chung; Gil Shalev; Efrat Shema; Dganit Shkedy; Nechama I Smorodinsky; Nicole van Vliet; Bernhard Kuster; Matthias Mann; Aaron Ciechanover; Jochen Dahm-Daphi; Roland Kanaar; Mickey C-T Hu; David J Chen; Moshe Oren; Yosef Shiloh
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

Review 3.  Epigenetic treatments for cognitive impairments.

Authors:  Jeremy J Day; J David Sweatt
Journal:  Neuropsychopharmacology       Date:  2011-05-18       Impact factor: 7.853

4.  Cancer: Let sleeping DNA lie.

Authors:  Ashok R Venkitaraman
Journal:  Nature       Date:  2011-09-07       Impact factor: 49.962

Review 5.  Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Tumour Biol       Date:  2012-03-06

6.  Interplay of H2A deubiquitinase 2A-DUB/Mysm1 and the p19(ARF)/p53 axis in hematopoiesis, early T-cell development and tissue differentiation.

Authors:  M Gatzka; A Tasdogan; A Hainzl; G Allies; P Maity; C Wilms; M Wlaschek; K Scharffetter-Kochanek
Journal:  Cell Death Differ       Date:  2015-01-23       Impact factor: 15.828

Review 7.  Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer.

Authors:  David Corujo; Marcus Buschbeck
Journal:  Cancers (Basel)       Date:  2018-02-27       Impact factor: 6.639

8.  Inhibiting Multiple Deubiquitinases to Reduce Androgen Receptor Expression in Prostate Cancer Cells.

Authors:  Alicia de Las Pozas; Teresita Reiner; Virginia De Cesare; Matthias Trost; Carlos Perez-Stable
Journal:  Sci Rep       Date:  2018-09-03       Impact factor: 4.379

9.  USP16 counteracts mono-ubiquitination of RPS27a and promotes maturation of the 40S ribosomal subunit.

Authors:  Christian Montellese; Jasmin van den Heuvel; Caroline Ashiono; Kerstin Dörner; André Melnik; Stefanie Jonas; Ivo Zemp; Paola Picotti; Ludovic C Gillet; Ulrike Kutay
Journal:  Elife       Date:  2020-03-04       Impact factor: 8.140

10.  Impact of high glucose and proteasome inhibitor MG132 on histone H2A and H2B ubiquitination in rat glomerular mesangial cells.

Authors:  Chenlin Gao; Guo Chen; Li Liu; Xia Li; Jianhua He; Lan Jiang; Jianhua Zhu; Yong Xu
Journal:  J Diabetes Res       Date:  2013-04-30       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.